What the company actually pays, and whether its own cash supports it.
Dividends view
Yield
0.36%Below 5Y avg (1.05%)
Annual Rate
CNY 0.03Paid annual
Payout Ratio
79.3%Moderate
Last Ex-Dividend
Jun 11, 2026
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
3.53BCNY
523.91M · vs all stocks (USD)
Updated Aug 19, 2026
Trailing P/E
55.06x
vs Diagnostics & Research peers
Updated Aug 19, 2026
Revenue (TTM)
1.54BCNY
228.89M · vs all stocks (USD)
Updated Aug 19, 2026
Profit Margin
4.32%
vs Diagnostics & Research peers
Updated Aug 19, 2026
Beta
0.3080x
vs all stocks
Updated Aug 19, 2026
52-Week Change
-20.50%
vs all stocks
Updated Aug 19, 2026
Market Capitalization
3.53BCNY
523.91M · vs all stocks (USD)
Updated Aug 19, 2026
Enterprise Value
2.80BCNY
416.08M · vs all stocks (USD)
Updated Aug 19, 2026
Trailing P/E
55.06x
vs Diagnostics & Research peers
Updated Aug 19, 2026
Forward P/E
8.00x
vs Diagnostics & Research peers
Updated Aug 19, 2026
Price to Sales (TTM)
2.33x
vs Diagnostics & Research peers
Updated Aug 19, 2026
Price to Book (MRQ)
1.20x
vs Diagnostics & Research peers
Updated Aug 19, 2026
Enterprise to Revenue
1.82x
vs Diagnostics & Research peers
Updated Aug 19, 2026
Enterprise to EBITDA
19.58x
vs Diagnostics & Research peers
Provider-reported. Enterprise Value ÷ EBITDA (TTM) on this page gives 23.4×.Updated Aug 19, 2026
Gross Margin
38.45%
vs Diagnostics & Research peers
Provider-reported. Gross Profit (TTM) ÷ Revenue (TTM) on this page gives 35.16%.Updated Aug 19, 2026
Profit Margin
4.32%
vs Diagnostics & Research peers
Updated Aug 19, 2026
Operating Margin
9.67%
vs Diagnostics & Research peers
Updated Aug 19, 2026
Return on Assets (TTM)
0.11%
vs Diagnostics & Research peers
Updated Aug 19, 2026
Return on Equity (TTM)
2.18%
vs Diagnostics & Research peers
Updated Aug 19, 2026
Revenue (TTM)
1.54BCNY
228.89M · vs all stocks (USD)
Updated Aug 19, 2026
Revenue per Share (TTM)
3.91CNYUpdated Aug 19, 2026
Quarterly Revenue Growth
0.50%
vs Diagnostics & Research peers
Updated Aug 19, 2026
Gross Profit (TTM)
541.84MCNY
80.47M · vs all stocks (USD)
Updated Aug 19, 2026
EBITDA (TTM)
119.71MCNY
17.78M · vs all stocks (USD)
Updated Aug 19, 2026
Net Income (TTM)
66.57MCNY
9.89M · vs all stocks (USD)
Updated Aug 19, 2026
Quarterly Earnings Growth (YoY)
11.10%
vs Diagnostics & Research peers
Updated Aug 19, 2026
Operating Cash Flow (TTM)
255.05MCNY
37.88M · vs all stocks (USD)
Updated Aug 19, 2026
Levered Free Cash Flow (TTM)
-42.40MCNY
-6.30M · vs all stocks (USD)
Updated Aug 19, 2026
Trailing Annual Dividend Rate
0.0330CNYUpdated Aug 19, 2026
Trailing Annual Dividend Yield
0.36%
vs all stocks
Updated Aug 19, 2026
5-Year Average Dividend Yield
1.05%
vs all stocks
Updated Aug 19, 2026
Payout Ratio
79.34%
vs Diagnostics & Research peers
Provider-reported. Trailing Annual Dividend Rate ÷ Diluted EPS (TTM) on this page gives 19.41%.Updated Aug 19, 2026
Minority Interest (Equity)
-6.58MCNYFY2025 · Dec 31, 2025
Revenue
1.54BCNYFY2025 · Dec 31, 2025
Cost of Goods Sold
972.74MCNYFY2025 · Dec 31, 2025
Gross Profit
566.42MCNYFY2025 · Dec 31, 2025
Operating Income
61.40MCNY
9.12M · vs all stocks (USD)
FY2025 · Dec 31, 2025
Pre-tax Income
46.09MCNYFY2025 · Dec 31, 2025
Income Tax Expense
-15.27MCNYFY2025 · Dec 31, 2025
Net Income
61.36MCNYFY2025 · Dec 31, 2025
EBIT
48.66MCNYFY2025 · Dec 31, 2025
EBITDA (Income Statement)
259.12MCNYFY2025 · Dec 31, 2025
Research & Development
127.20MCNYFY2025 · Dec 31, 2025
Selling, General & Administrative
146.68MCNYFY2025 · Dec 31, 2025
Other Operating Expenses
19.08MCNYFY2025 · Dec 31, 2025
Non-operating Interest Income
3.88MCNYFY2025 · Dec 31, 2025
Non-operating Interest Expense
2.57MCNYFY2025 · Dec 31, 2025
EPS (Basic)
0.1600CNYFY2025 · Dec 31, 2025
EPS (Diluted)
0.1600CNYFY2025 · Dec 31, 2025
Basic Shares Outstanding
395.01MSharesFY2025 · Dec 31, 2025
Diluted Shares Outstanding
395.01MSharesFY2025 · Dec 31, 2025
Net Income from Continuing Operations
61.36MCNYFY2025 · Dec 31, 2025
Minority Interests (P&L)
1.84MCNYFY2025 · Dec 31, 2025
Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025
Operating Cash Flow
15.84MCNYFY2025 · Dec 31, 2025
Free Cash Flow
-170.38MCNYFY2025 · Dec 31, 2025
Cash & Cash Equivalents (End of Period)
657.44MCNYFY2025 · Dec 31, 2025
Starting Profit (CF Statement)
61.36MCNYFY2025 · Dec 31, 2025
Other Non-cash Items
15.76MCNYFY2025 · Dec 31, 2025
Change in Accounts Receivable (CF)
-64.04MCNYFY2025 · Dec 31, 2025
Change in Other Assets/Liabilities
2.76MCNYFY2025 · Dec 31, 2025
Capital Expenditures
-186.22MCNYFY2025 · Dec 31, 2025
Net Acquisitions
363.08KCNYFY2025 · Dec 31, 2025
Purchase of Investments
-1.07BCNYFY2025 · Dec 31, 2025
Sale of Investments
994.50MCNYFY2025 · Dec 31, 2025
Net Investing Cash Flow
-258.35MCNYFY2025 · Dec 31, 2025
Long-term Debt Issuance
34.84MCNYFY2025 · Dec 31, 2025
Long-term Debt Payments
-45.00MCNYFY2025 · Dec 31, 2025
Common Dividends Paid
-51.99MCNYFY2025 · Dec 31, 2025
Other Financing Charges
-14.56MCNYFY2025 · Dec 31, 2025
Net Financing Cash Flow
-76.71MCNYFY2025 · Dec 31, 2025
Shares Outstanding
384.32MSharesUpdated Aug 19, 2026
Float Shares
202.63MSharesUpdated Aug 19, 2026
% Held by Insiders
49.18%
vs all stocks
Updated Aug 19, 2026
% Held by Institutions
0.89%
vs all stocks
Updated Aug 19, 2026
Total Cash (MRQ)
827.43MCNY
122.89M · vs all stocks (USD)
Updated Aug 19, 2026
Total Cash per Share (MRQ)
2.15CNYUpdated Aug 19, 2026
Total Debt (MRQ)
38.17MCNY
5.67M · vs all stocks (USD)
Updated Aug 19, 2026
Total Debt to Equity (MRQ)
0.0128x
vs Diagnostics & Research peers
Updated Aug 19, 2026
Current Ratio (MRQ)
3.46x
vs Diagnostics & Research peers
Updated Aug 19, 2026
Book Value per Share (MRQ)
7.77CNYUpdated Aug 19, 2026
Total Assets
3.65BCNY
542.65M · vs all stocks (USD)
FY2025 · Dec 31, 2025
Total Current Assets
1.89BCNYFY2025 · Dec 31, 2025
Total Liabilities
706.06MCNYFY2025 · Dec 31, 2025
Total Non-current Assets
1.76BCNYFY2025 · Dec 31, 2025
Total Non-current Liabilities
82.08MCNYFY2025 · Dec 31, 2025
Total Current Liabilities
623.99MCNYFY2025 · Dec 31, 2025
Cash
657.57MCNYFY2025 · Dec 31, 2025
Cash & Cash Equivalents
657.57MCNYFY2025 · Dec 31, 2025
Other Short-term Investments
265.43MCNYFY2025 · Dec 31, 2025
Accounts Receivable
581.39MCNYFY2025 · Dec 31, 2025
Inventory
231.07MCNYFY2025 · Dec 31, 2025
Accounts Payable
356.41MCNYFY2025 · Dec 31, 2025
Short-term Debt
31.48MCNYFY2025 · Dec 31, 2025
Other Current Liabilities
10.50MCNYFY2025 · Dec 31, 2025
Long-term Debt
27.74MCNYFY2025 · Dec 31, 2025
Other Non-current Liabilities
1.37MCNYFY2025 · Dec 31, 2025
Common Stock (Book)
384.32MCNYFY2025 · Dec 31, 2025
Retained Earnings
1.34BCNYFY2025 · Dec 31, 2025
Total Shareholders' Equity
2.95BCNY
437.78M · vs all stocks (USD)
FY2025 · Dec 31, 2025
Treasury Stock
2.91MCNYFY2025 · Dec 31, 2025
52-Week Low
7.83CNYUpdated Aug 19, 2026
52-Week High
11.75CNYUpdated Aug 19, 2026
52-Week Change
-20.50%
vs all stocks
Updated Aug 19, 2026
Beta
0.3080x
vs all stocks
Updated Aug 19, 2026
50-Day MA
8.59CNYUpdated Aug 19, 2026
200-Day MA
9.71CNYUpdated Aug 19, 2026
Avg 10-Day Volume
4.65MSharesUpdated Aug 19, 2026
Avg 30-Day Volume
4.11MSharesUpdated Aug 19, 2026
Diluted EPS (TTM)
0.1700CNYUpdated Aug 19, 2026
3 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Profits kept in the business fund much of what it owns, and it now pays out most of what it earns.
Reads
How does this company use capital?
Minimal Tax and Interest Drag
Almost nothing is lost between its operating profit and its net income.
Reads
How is this stock valued?
High Retained Earnings With Profitability And Equity
Profits kept in the business fund much of what it owns, after five straight profitable years.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.